While we're still sorting the details between the new legislation and interchangeability regarding Biosimilars, the EU market is already in development stages for even later patent expiries. Recent studies show that 88 products are in various stages of development, with 75 of the products currently active. The EU market is also currently increasing in complex biologics, as well as second wave of Biosimilars.
View a presentation of key findings of 88 marketed and development stage EU biosimilars below:
To learn more about the recent EU Market and Biosimilars join us October 15-17 in Boston, MA for the 14th Annual Business of Biosimilars Conference. For more information, view our agenda. We look forward to seeing you this fall!
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment